Khiron Life Sciences is one of four cannabis stocks in the January Top 40

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Two big themes emerge in the January INK Edge Top 40 Stock Report distributed Wednesday morning to Canadian Insider Club members. First, bargain hunters have something to cheer about with eight stocks making the list that rank highly in terms of offering cheap valuations. Secondly, four cannabis-oriented stocks (which we would categorize as growth story stocks) make the list this month. That's a first for the Top 40 as insiders had been more inclined to sell pot stocks than buy. Now, there are a handful where just the opposite is taking place.

Khiron Life Sciences is a Latin America-focused cannabis company

One of the cannabis names in the Top 40 with insider buying is December 14th Morning INK stock Khiron Life Sciences (KHRN) focused on Latin America. As reported in the INK December morning report feature, Khiron develops and commercializes medical cannabis products mainly in Colombia and is active in the research area. Early last month, the company announced it had completed the acquisition of the Latin American Institute of Neurology and the Nervous System ((ILANS). According to Khiron, the ILANS network represents 100,000 patients in Colombia and believes the acquisition will provide a scalable revenue stream with opportunities to introduce medical cannabis to ILANS patients. 


Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).